Evogene

EVGN · NASDAQ

$0.3716+$0.0036 (+0.98%)TodayMarket closed ·
Prev close $0.368

About EVGN

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 142 full-time employees. The company went IPO on 2007-06-11. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees
142
Headquarters
Rehovot, Central(HaMerkaz)
Listed
Jun 11, 2007
Sector
Health Care
Industry
Biotechnology

Leadership

Evogene executives
NameTitleSince
Nir Nimrodi—2025
Ofer Haviv—2002
Dorit Kreiner——
Brian Ember——
Elran Haber——
Arnon Heyman——
Mark Kapel——
Sassi Masliah——
Nir Arbel——
Dan Falk——
Sarit Firon——
Ziv Kop——
Adrian Percy——
Leon Recanati——
Oded Shoseyov——
Kenny Green—2022

Revenue by product and region

Fiscal year ended Dec 31, 2025: $3.85M total revenue

By product

  • Industrial application [Member]$2.17M56.3%
  • Agriculture [Member]$1.37M35.7%
  • Unallocated [Member]$311.00K8.1%

Similar companies

Companies in the same industry as Evogene

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.